Geneos Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $50.2K | Hold |
101
| – | – | ﹤0.01% | 1460 |
|
|
2026
Q1 | $45.1K | Sell |
101
-1
| -1% | -$466 | ﹤0.01% | 1470 |
|
|
2025
Q4 | $46.2K | Sell |
102
-15
| -13% | -$6.46K | ﹤0.01% | 1422 |
|
|
2025
Q3 | $45.8K | Sell |
117
-1,775
| -94% | -$742K | ﹤0.01% | 1422 |
|
|
2025
Q2 | $842K | Sell |
1,892
-3,021
| -61% | -$1.39M | 0.02% | 580 |
|
|
2025
Q1 | $2.38M | Buy |
4,913
+3,460
| +238% | +$1.61M | 0.03% | 446 |
|
|
2024
Q4 | $585K | Sell |
1,453
-244
| -14% | -$113K | 0.02% | 548 |
|
|
2024
Q3 | $789K | Buy |
1,697
+1,623
| +2,193% | +$780K | 0.03% | 453 |
|
|
2024
Q2 | $34.7K | Buy |
74
+5
| +7% | +$2.17K | ﹤0.01% | 1195 |
|
|
2024
Q1 | $28.8K | Sell |
69
-15
| -18% | -$6.34K | ﹤0.01% | 1255 |
|
|
2023
Q4 | $34.2K | Sell |
84
-107
| -56% | -$39.5K | ﹤0.01% | 1188 |
|
|
2023
Q3 | $66.4K | Buy |
191
+54
| +39% | +$18.9K | ﹤0.01% | 992 |
|
|
2023
Q2 | $48.2K | Buy |
137
+130
| +1,857% | +$43.8K | ﹤0.01% | 1087 |
|
|
2023
Q1 | $2.21K | Sell |
7
-120
| -94% | -$36K | ﹤0.01% | 1887 |
|
|
2022
Q4 | $36.7K | Hold |
127
| – | – | ﹤0.01% | 1157 |
|
|
2022
Q3 | $36K | Sell |
127
-318
| -71% | -$91.5K | ﹤0.01% | 1136 |
|
|
2022
Q2 | $127K | Hold |
445
| – | – | 0.01% | 918 |
|
|
2022
Q1 | $116K | Buy |
445
+120
| +37% | +$28.5K | 0.01% | 1026 |
|
|
2021
Q4 | $71K | Buy |
325
+100
| +44% | +$19.4K | ﹤0.01% | 1319 |
|
|
2021
Q3 | $40K | Buy |
225
+1
| +0.4% | +$195 | ﹤0.01% | 1599 |
|
|
2021
Q2 | $44K | Sell |
224
-2,380
| -91% | -$498K | ﹤0.01% | 1545 |
|
|
2021
Q1 | $568K | Sell |
2,604
-354
| -12% | -$77.8K | 0.02% | 607 |
|
|
2020
Q4 | $605K | Buy |
2,958
+2,350
| +387% | +$539K | 0.02% | 483 |
|
|
2020
Q3 | $163K | Sell |
608
-300
| -33% | -$82.8K | 0.01% | 757 |
|
|
2020
Q2 | $259K | Buy |
908
+270
| +42% | +$73.2K | 0.01% | 588 |
|
|
2020
Q1 | $138K | Buy |
638
+100
| +19% | +$22.9K | 0.01% | 737 |
|
|
2019
Q4 | $118K | Hold |
538
| – | – | 0.01% | 888 |
|
|
2019
Q3 | $89K | Buy |
538
+14
| +3% | +$2.48K | 0.01% | 940 |
|
|
2019
Q2 | $96K | Sell |
524
-50
| -9% | -$8.74K | 0.01% | 926 |
|
|
2019
Q1 | $105K | Sell |
574
-24
| -4% | -$4.43K | 0.01% | 850 |
|
|
2018
Q4 | $96K | Hold |
598
| – | – | 0.01% | 851 |
|
|
2018
Q3 | $115K | Buy |
598
+29
| +5% | +$5.16K | 0.01% | 841 |
|
|
2018
Q2 | $96K | Sell |
569
-70
| -11% | -$10.9K | 0.01% | 802 |
|
|
2018
Q1 | $104K | Hold |
639
| – | – | 0.01% | 741 |
|
|
2017
Q4 | $95K | Sell |
639
-67
| -9% | -$9.92K | 0.01% | 763 |
|
|
2017
Q3 | $107K | Buy |
706
+453
| +179% | +$68.2K | 0.01% | 679 |
|
|
2017
Q2 | $32K | Hold |
253
| – | – | ﹤0.01% | 1103 |
|
|
2017
Q1 | $27K | Sell |
253
-22
| -8% | -$1.94K | ﹤0.01% | 1135 |
|
|
2016
Q4 | $20K | Hold |
275
| – | – | ﹤0.01% | 1190 |
|
|
2016
Q3 | $23K | Buy |
275
+22
| +9% | +$2.08K | ﹤0.01% | 1091 |
|
|
2016
Q2 | $22K | Hold |
253
| – | – | ﹤0.01% | 1093 |
|
|
2016
Q1 | $20K | Buy |
+253
| New | +$22.9K | ﹤0.01% | 1095 |
|
Other funds holding VRTX
Geneos Wealth Management's VRTX Position: Q2 2026 in Review
Geneos Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 101 shares worth $50.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1460.
Geneos Wealth Management first reported a position in VRTX in Q1 2016 and has held it in 42 quarters since. The position peaked at $2.38M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Geneos Wealth Management held 101 shares of Vertex Pharmaceuticals worth $50.2K as of Q2 2026.
- Geneos Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
- Vertex Pharmaceuticals made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #1460 holding.
- Geneos Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 42 quarters since.
- Geneos Wealth Management's Vertex Pharmaceuticals position peaked at $2.38M in Q1 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.